Understanding inherited and environmental risk for lymphomas and multiple myeloma
Official title: InterLymph Consortium: interrogating pleiotropy and gene by environment interactions among hematopoietic malignancies.
Funded at International Agency for Res on Cancer · NIH-11159756 · Data updated 2026-11-12
This project uses genetic information and environmental histories to improve how we identify people at higher risk for lymphoma and multiple myeloma.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | International Agency for Res on Cancer NIH-funded |
| Lab location | 1 site (Lyon, France) |
| Project start | September 3, 2021 |
| Project end | August 31, 2026 |
| Funding year | 2025 |
| Award (this year) | $544,532 |
| NIH project number | 5U01CA257679-05 |
| Project ID | NIH-11159756 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal participants are people diagnosed with Hodgkin lymphoma, non‑Hodgkin lymphoma, or multiple myeloma who can provide genetic samples and information about environmental exposures.
✕Less likely to help
People without lymphoid cancers or those unwilling/unable to provide genetic or exposure information are unlikely to gain direct benefit from participating.
What this research studies
Researchers are combining DNA and health-history information from tens of thousands of people with Hodgkin lymphoma, non‑Hodgkin lymphoma, and multiple myeloma plus many controls to find genetic differences linked to risk. They will build and test polygenic risk scores from genome‑wide data and validate those scores in an independent group of patients. The team will also look at how genetic profiles interact with chemical and other environmental exposures to understand combined effects on subtype risk. Findings aim to clarify why some people develop specific lymphoma subtypes and who may be at greater risk.
Why it matters
Potential benefit: If successful, this work could improve early identification of people at higher risk and help guide prevention or targeted screening strategies.
How similar studies have gone: Previous InterLymph genome‑wide studies have identified risk variants and polygenic risk approaches show promise, but applying large‑scale gene–environment interaction analyses across many lymphoma subtypes is a newer effort.
Where this research is happening
-
International Agency for Res on Cancer
Lyon, France Active
Researchers
- Principal investigator: Mckay, James Dowling — International Agency for Res on Cancer
- Study coordinator: Mckay, James Dowling
Related research
Other NIH-funded projects on the same topics.
-
A fast, affordable AI-enabled system to screen and guide treatment for cervical cancer in LMICs
A new AI-assisted system will screen for cervical precancers and help choose the best treatment for women in low- and middle-income countries and the United States.
-
Affordable AI-Powered cervical cancer screening and treatment guide for LMICs
A new AI-based system helps screen, triage, and choose treatments for cervical pre-cancer and cancer in low- and middle-income countries.
-
Opioid use and cancer risk across populations
This grant checks whether using prescription opioids is linked to cancer risk by pooling data from lots of studies and health records across several countries.
-
Proteogenomic framework to improve lung cancer screening with biomarkers
A biomarker-based approach aims to refine LDCT lung cancer screening so more cancers are caught early while reducing unnecessary procedures.
-
AI-powered cervical cancer screening and treatment guidance for LMICs
A new AI-based system helps screen for cervical cancer and guide treatment choices for women in low- and middle-income countries.
-
Affordable AI-powered one-stop cervical cancer screening, triage, and treatment aid for women in LMICs
This project is building an affordable, AI-powered system to screen women in low- and middle-income countries for high-risk HPV from urine, read cervical photos to spot precancer, and help guide treatment choices.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.